Health Protection Agency (Porton) Debate

Full Debate: Read Full Debate
Department: Department of Health and Social Care

Health Protection Agency (Porton)

Robert Halfon Excerpts
Tuesday 22nd June 2010

(14 years, 3 months ago)

Commons Chamber
Read Full debate Read Hansard Text Read Debate Ministerial Extracts
Robert Halfon Portrait Robert Halfon (Harlow) (Con)
- Hansard - -

I thank my hon. Friend the Member for Salisbury (John Glen) for being utterly decent in giving me a couple of minutes to respond, given our conflicting constituency interests. It is much appreciated.

Mr. Deputy Speaker, you would expect me to seek investment in Harlow—I am the local Member of Parliament. However, that view is not just mine; it is also that of the Health Protection Agency. Its board concluded that, for pure cost-effectiveness and value for money, the HPA must move to Harlow. The foreword to its “Outline Business Case” states:

“Relocating to Harlow is the preferred option. It offers excellent value for money. In addition to significant savings, and reduction of overheads, there are major benefits.”

What are the facts? We know that the 50-year-old site in Porton Down is rapidly approaching the end of its life and that it would be expensive to refurbish—it would cost almost the same as buying the GSK facility, and offers little strategic value. We know that the option of staying at Porton Down was fully considered in the business case and rejected on the ground of poor value for money. We know that GSK will sell its Harlow facility to the HPA for 30% cheaper than the construction cost, so moving to Harlow is a bargain for the taxpayer. We also know that there are strategic benefits for the HPA in Harlow—the London-Cambridge corridor is the heart of biomedical research in the UK. Moving closer to its north London facilities will ultimately save HPA money because it can substantially reduce its overheads. Moving to Harlow would increase the HPA’s capacity. The economic benefits have been assessed as “in excess of £100 billion” over the lifetime of the new site.

For the record, I must say that GlaxoSmithKline is a huge local employer in Harlow, and that it recently announced up to 1,000 redundancies. Unemployment in my town is already the highest in west Essex. Sadly, some estates in Harlow are among the most deprived in Britain, but the investment would transform economic prospects in Harlow.

The 50-year-old site in Porton Down is too expensive to repair. We have a good deal in Harlow, and we must take it. The huge regeneration that it would bring to the town is desperately needed, but I urge my hon. Friend the Under-Secretary of State for Health to base the decision primarily on the business case and value for money.